Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.

Press MF, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Tsao-Wei DD, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ.

J Clin Oncol. 2016 Oct 10;34(29):3518-3528. doi: 10.1200/JCO.2016.66.6693.

2.

Tissue Microarrays.

Dancau AM, Simon R, Mirlacher M, Sauter G.

Methods Mol Biol. 2016;1381:53-65. doi: 10.1007/978-1-4939-3204-7_3.

PMID:
26667454
3.

Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer.

Melling N, Simon R, Mirlacher M, Izbicki JR, Stahl P, Terracciano LM, Bokemeyer C, Sauter G, Marx AH.

Histopathology. 2016 Jan;68(2):191-8. doi: 10.1111/his.12726. Epub 2015 Jul 22.

PMID:
25922889
4.

Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene.

Fleischmann A, Huland H, Mirlacher M, Wilczak W, Simon R, Erbersdobler A, Sauter G, Schlomm T.

Prostate. 2012 Jun 15;72(9):991-7. doi: 10.1002/pros.21504. Epub 2011 Oct 24.

PMID:
22024950
5.

The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers.

Tennstedt P, Köster P, Brüchmann A, Mirlacher M, Haese A, Steuber T, Sauter G, Huland H, Graefen M, Schlomm T, Minner S, Simon R.

Int J Oncol. 2012 Jan;40(1):261-8. doi: 10.3892/ijo.2011.1216. Epub 2011 Sep 28.

PMID:
21956230
6.

Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis.

Marx AH, Zielinski M, Kowitz CM, Dancau AM, Thieltges S, Simon R, Choschzick M, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Brümmendorf TH, Fiedler W, Bokemeyer C, Izbicki JR, Sauter G.

Histopathology. 2010 Sep;57(3):418-26. doi: 10.1111/j.1365-2559.2010.03643.x. Epub 2010 Aug 31.

PMID:
20840671
7.

Immunohistochemical analysis of tissue microarrays.

Simon R, Mirlacher M, Sauter G.

Methods Mol Biol. 2010;664:113-26. doi: 10.1007/978-1-60761-806-5_12.

PMID:
20690058
8.

Recipient block TMA technique.

Mirlacher M, Simon R.

Methods Mol Biol. 2010;664:37-44. doi: 10.1007/978-1-60761-806-5_4.

PMID:
20690050
9.

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR.

Hum Pathol. 2010 Nov;41(11):1577-85. doi: 10.1016/j.humpath.2010.02.018. Epub 2010 Jul 24.

PMID:
20656317
10.

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.

Minner S, Jessen B, Stiedenroth L, Burandt E, Köllermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brümmendorf TH, Bokemeyer C, Simon R, Steuber T, Graefen M, Huland H, Sauter G, Schlomm T.

Clin Cancer Res. 2010 Mar 1;16(5):1553-60. doi: 10.1158/1078-0432.CCR-09-2546. Epub 2010 Feb 23.

11.

Tissue microarrays.

Dancau AM, Simon R, Mirlacher M, Sauter G.

Methods Mol Biol. 2010;576:49-60. doi: 10.1007/978-1-59745-545-9_4.

PMID:
19882257
12.

Prognostic value of microvessel density in prostate cancer: a tissue microarray study.

Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A.

World J Urol. 2010 Dec;28(6):687-92. doi: 10.1007/s00345-009-0471-4. Epub 2009 Aug 28.

PMID:
19714336
13.

Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study.

Erbersdobler A, Isbarn H, Steiner I, Schlomm T, Chun F, Mirlacher M, Sauter G.

Urology. 2009 Nov;74(5):1169-73. doi: 10.1016/j.urology.2009.02.061. Epub 2009 May 24.

PMID:
19476978
14.

HER-2/neu analysis in breast cancer bone metastases.

Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jaenicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G.

J Clin Pathol. 2009 Jun;62(6):542-6. doi: 10.1136/jcp.2008.059717.

PMID:
19474354
15.

Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.

Fleischmann A, Schlomm T, Köllermann J, Sekulic N, Huland H, Mirlacher M, Sauter G, Simon R, Erbersdobler A.

Prostate. 2009 Jun 15;69(9):976-81. doi: 10.1002/pros.20948.

PMID:
19274666
16.

HER-2 amplification is highly homogenous in gastric cancer.

Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Brümmendorf TH, Bokemeyer C, Izbicki JR, Sauter G.

Hum Pathol. 2009 Jun;40(6):769-77. doi: 10.1016/j.humpath.2008.11.014. Epub 2009 Mar 9.

PMID:
19269014
17.

Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients.

Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A.

Clin Cancer Res. 2008 Dec 1;14(23):7838-42. doi: 10.1158/1078-0432.CCR-08-1432.

18.

Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.

Marx A, Wandrey T, Simon P, Wewer A, Grob T, Reichelt U, Minner S, Simon R, Spehlmann M, Tigges W, Soehendra N, Seitz U, Seewald S, Izbicki JR, Yekebas E, Kaifi JT, Mirlacher M, Terracciano L, Fleischmann A, Raedler A, Sauter G.

Hum Pathol. 2009 Feb;40(2):166-73. doi: 10.1016/j.humpath.2008.06.027. Epub 2008 Oct 5.

PMID:
18835622
19.

AMACR expression in colorectal cancer is associated with left-sided tumor localization.

Marx A, Simon P, Simon R, Mirlacher M, Izbicki JR, Yekebas E, Kaifi JT, Terracciano L, Sauter G.

Virchows Arch. 2008 Sep;453(3):243-8. doi: 10.1007/s00428-008-0646-1. Epub 2008 Aug 19.

PMID:
18712414
20.

Clinical significance of p53 alterations in surgically treated prostate cancers.

Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A.

Mod Pathol. 2008 Nov;21(11):1371-8. doi: 10.1038/modpathol.2008.104. Epub 2008 Jun 13.

21.

Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.

Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter G.

Mod Pathol. 2007 Feb;20(2):192-8.

22.

Molecular staging of prostate cancer in the year 2007.

Schlomm T, Erbersdobler A, Mirlacher M, Sauter G.

World J Urol. 2007 Mar;25(1):19-30. Epub 2007 Mar 2. Review.

PMID:
17334767
23.

E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer.

Oeggerli M, Schraml P, Ruiz C, Bloch M, Novotny H, Mirlacher M, Sauter G, Simon R.

Oncogene. 2006 Oct 19;25(49):6538-43. Epub 2006 Sep 4.

PMID:
16953223
24.

HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.

Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo L.

J Clin Pathol. 2007 Jul;60(7):768-72. Epub 2006 Aug 1.

25.

Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue.

Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA.

Arch Pathol Lab Med. 2006 Jul;130(7):989-96.

PMID:
16831056
26.

Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer.

Woenckhaus M, Bubendorf L, Dalquen P, Foerster J, Blaszyk H, Mirlacher M, Soler M, Dietmaier W, Sauter G, Hartmann A, Wild PJ.

J Clin Pathol. 2007 May;60(5):483-6. Epub 2006 May 12.

27.

Epithelial growth factor receptor status in primary and recurrent ovarian cancer.

Stadlmann S, Gueth U, Reiser U, Diener PA, Zeimet AG, Wight E, Mirlacher M, Sauter G, Mihatsch MJ, Singer G.

Mod Pathol. 2006 Apr;19(4):607-10.

28.

Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.

Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G.

Int J Cancer. 2006 May 1;118(9):2190-4.

29.

Increased apolipoprotein deposits in early atherosclerotic lesions distinguish symptomatic from asymptomatic patients.

Wyler von Ballmoos M, Dubler D, Mirlacher M, Cathomas G, Muser J, Biedermann BC.

Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):359-64. Epub 2005 Dec 1.

PMID:
16322531
30.

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Press MF, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, Zhou JY, Wardeh R, Li YT, Guzman R, Ma Y, Sullivan-Halley J, Santiago A, Park JM, Riva A, Slamon DJ.

Clin Cancer Res. 2005 Sep 15;11(18):6598-607.

31.

EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers.

Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L.

Clin Cancer Res. 2005 Sep 15;11(18):6450-8.

32.

Tissue microarrays.

Simon R, Mirlacher M, Sauter G.

Methods Mol Med. 2005;114:257-68.

PMID:
16156109
33.

Predominance of high-grade pathway in breast cancer development of Middle East women.

Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter G.

Mod Pathol. 2005 Jul;18(7):891-7.

34.

Prognostic relevance of gene amplifications and coamplifications in breast cancer.

Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter G.

Cancer Res. 2004 Dec 1;64(23):8534-40.

35.

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, Maurer R, Metzger U, von Castelberg B, Bart R, Stopatschinskaya S, Köchli OR, Haas P, Mross F, Zuber M, Dietrich H, Bischoff S, Mirlacher M, Sauter G, Gastl G.

Breast Cancer Res Treat. 2004 Aug;86(3):207-13.

PMID:
15567937
36.

Expression and amplification of therapeutic target genes in retinoblastoma.

Bösch D, Pache M, Simon R, Schraml P, Glatz K, Mirlacher M, Flammer J, Sauter G, Meyer P.

Graefes Arch Clin Exp Ophthalmol. 2005 Feb;243(2):156-62. Epub 2004 Nov 10.

PMID:
15549365
37.

HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.

Tapia C, Schraml P, Simon R, Al-Kuraya KS, Maurer R, Mirlacher M, Novotny H, Spichtin H, Mihatsch MJ, Sauter G.

Int J Oncol. 2004 Dec;25(6):1551-7.

PMID:
15547690
38.

Prevalence of KIT expression in human tumors.

Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G.

J Clin Oncol. 2004 Nov 15;22(22):4514-22.

PMID:
15542802
39.

Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis.

Fleiner M, Kummer M, Mirlacher M, Sauter G, Cathomas G, Krapf R, Biedermann BC.

Circulation. 2004 Nov 2;110(18):2843-50. Epub 2004 Oct 25.

PMID:
15505090
40.

Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.

Lugli A, Tornillo L, Mirlacher M, Bundi M, Sauter G, Terracciano LM.

Am J Clin Pathol. 2004 Nov;122(5):721-7.

PMID:
15491968
41.

Expression patterns of potential therapeutic targets in prostate cancer.

Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L.

Int J Cancer. 2005 Feb 10;113(4):619-28.

42.

Tissue microarrays for early target evaluation.

Simon R, Mirlacher M, Sauter G.

Drug Discov Today Technol. 2004 Sep;1(1):41-8. doi: 10.1016/j.ddtec.2004.08.003.

PMID:
24981266
43.

TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer.

Zheng M, Simon R, Mirlacher M, Maurer R, Gasser T, Forster T, Diener PA, Mihatsch MJ, Sauter G, Schraml P.

Am J Pathol. 2004 Jul;165(1):63-9.

44.

Influence of slide aging on results of translational research studies using immunohistochemistry.

Mirlacher M, Kasper M, Storz M, Knecht Y, Dürmüller U, Simon R, Mihatsch MJ, Sauter G.

Mod Pathol. 2004 Nov;17(11):1414-20.

45.

The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.

Kaimaktchiev V, Terracciano L, Tornillo L, Spichtin H, Stoios D, Bundi M, Korcheva V, Mirlacher M, Loda M, Sauter G, Corless CL.

Mod Pathol. 2004 Nov;17(11):1392-9.

46.

Tissue microarrays.

Simon R, Mirlacher M, Sauter G.

Methods Mol Med. 2004;97:377-89. No abstract available.

PMID:
15064506
47.

Impaired expression of the cell cycle regulator BTG2 is common in clear cell renal cell carcinoma.

Struckmann K, Schraml P, Simon R, Elmenhorst K, Mirlacher M, Kononen J, Moch H.

Cancer Res. 2004 Mar 1;64(5):1632-8.

48.

Frequent EpCam protein expression in human carcinomas.

Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, Dirnhofer S.

Hum Pathol. 2004 Jan;35(1):122-8.

PMID:
14745734
49.

Tissue microarrays.

Simon R, Mirlacher M, Sauter G.

Biotechniques. 2004 Jan;36(1):98-105. Review.

50.

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, Mirlacher M, Rufle A, Torhorst J, Sauter G.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83.

Supplemental Content

Loading ...
Support Center